Mark Halvorson

Array ( [id] => 15668881 [patent_doc_number] => 10598663 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-24 [patent_title] => Methods and biomarkers for analysis of colorectal cancer [patent_app_type] => utility [patent_app_number] => 15/302728 [patent_app_country] => US [patent_app_date] => 2015-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 4 [patent_no_of_words] => 7681 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 134 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15302728 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11443548 [patent_doc_number] => 20170044569 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2017-02-16 [patent_title] => 'RNA-Guided Human Genome Engineering' [patent_app_type] => utility [patent_app_number] => 14/681510 [patent_app_country] => US [patent_app_date] => 2015-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 42 [patent_no_of_words] => 9883 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14681510 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11443548 [patent_doc_number] => 20170044569 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2017-02-16 [patent_title] => 'RNA-Guided Human Genome Engineering' [patent_app_type] => utility [patent_app_number] => 14/681510 [patent_app_country] => US [patent_app_date] => 2015-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 42 [patent_no_of_words] => 9883 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14681510 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11880775 [patent_doc_number] => 09751934 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-09-05 [patent_title] => 'Monoclonal antibodies against claudin-18 for treatment of cancer' [patent_app_type] => utility [patent_app_number] => 14/661882 [patent_app_country] => US [patent_app_date] => 2015-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 51 [patent_figures_cnt] => 64 [patent_no_of_words] => 39774 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14661882 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10367098 [patent_doc_number] => 20150252103 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-09-10 [patent_title] => 'MONOCLONAL ANTIBODIES AGAINST CLAUDIN-18 FOR TREATMENT OF CANCER' [patent_app_type] => utility [patent_app_number] => 14/661846 [patent_app_country] => US [patent_app_date] => 2015-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 51 [patent_figures_cnt] => 51 [patent_no_of_words] => 39804 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14661846 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10374400 [patent_doc_number] => 20150259407 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-09-17 [patent_title] => 'csPCNA Isoform Antibodies And Uses Thereof' [patent_app_type] => utility [patent_app_number] => 14/645498 [patent_app_country] => US [patent_app_date] => 2015-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 16262 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14645498 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11471251 [patent_doc_number] => 20170058035 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-02 [patent_title] => 'ANTIBODIES THAT BIND EGFR AND ERBB3' [patent_app_type] => utility [patent_app_number] => 15/121619 [patent_app_country] => US [patent_app_date] => 2015-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 46 [patent_no_of_words] => 24958 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15121619 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10422591 [patent_doc_number] => 20150307602 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-29 [patent_title] => 'ANTI-POLYUBIQUITIN ANTIBODIES AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 14/627597 [patent_app_country] => US [patent_app_date] => 2015-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 37085 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14627597 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10305486 [patent_doc_number] => 20150190485 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-09 [patent_title] => 'PEPTIDE CONJUGATED PARTICLES' [patent_app_type] => utility [patent_app_number] => 14/624463 [patent_app_country] => US [patent_app_date] => 2015-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 47 [patent_no_of_words] => 36870 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14624463 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10265944 [patent_doc_number] => 20150150941 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-04 [patent_title] => 'CHRONIC LYMPHOCYTIC LEUKEMIA PROGNOSIS AND TREATMENT' [patent_app_type] => utility [patent_app_number] => 14/615939 [patent_app_country] => US [patent_app_date] => 2015-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 11635 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14615939 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10347521 [patent_doc_number] => 20150232525 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-20 [patent_title] => 'ANTI-TUMOUR RESPONSE TO MODIFIED SELF-EPITOPES' [patent_app_type] => utility [patent_app_number] => 14/614964 [patent_app_country] => US [patent_app_date] => 2015-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 63 [patent_figures_cnt] => 63 [patent_no_of_words] => 28794 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14614964 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10255038 [patent_doc_number] => 20150140035 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-05-21 [patent_title] => 'AUTOLOGOUS BIOLOGICAL CANCER VACCINE' [patent_app_type] => utility [patent_app_number] => 14/603973 [patent_app_country] => US [patent_app_date] => 2015-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 9492 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14603973 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10354981 [patent_doc_number] => 20150239986 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-27 [patent_title] => 'ANTIBODIES AND MOLECULES DERIVED THEREFROM THAT BIND TO STEAP-1 PROTEINS' [patent_app_type] => utility [patent_app_number] => 14/604658 [patent_app_country] => US [patent_app_date] => 2015-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 87 [patent_figures_cnt] => 87 [patent_no_of_words] => 89686 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14604658 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13280353 [patent_doc_number] => 10151754 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-12-11 [patent_title] => Cell surface prostate cancer antigen for diagnosis [patent_app_type] => utility [patent_app_number] => 15/111973 [patent_app_country] => US [patent_app_date] => 2015-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 14 [patent_no_of_words] => 16291 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 200 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15111973 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12118805 [patent_doc_number] => 20180002391 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-04 [patent_title] => 'GLYPICAN EPITOPES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/543877 [patent_app_country] => US [patent_app_date] => 2015-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 22367 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15543877 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11127888 [patent_doc_number] => 20160324863 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-10 [patent_title] => 'TARGETED CANCER TREATMENT BY HSP90 INHIBITORS GANETESPIB AND NVP-AUY922' [patent_app_type] => utility [patent_app_number] => 15/111977 [patent_app_country] => US [patent_app_date] => 2015-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 36 [patent_no_of_words] => 36852 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15111977 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10255044 [patent_doc_number] => 20150140041 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-05-21 [patent_title] => 'PERSONALIZED CANCER VACCINES AND ADOPTIVE IMMUNE CELL THERAPIES' [patent_app_type] => utility [patent_app_number] => 14/594757 [patent_app_country] => US [patent_app_date] => 2015-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 15438 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14594757 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10312540 [patent_doc_number] => 20150197542 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-16 [patent_title] => 'METHOD OF PURIFICATION OF ANTI-C-MET ANTIBODY' [patent_app_type] => utility [patent_app_number] => 14/595027 [patent_app_country] => US [patent_app_date] => 2015-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 21383 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14595027 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10225812 [patent_doc_number] => 20150110805 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-04-23 [patent_title] => 'THERAPEUTIC STRATEGY FOR TREATING AUTOIMMUNE AND DEGENERATIVE DISEASES' [patent_app_type] => utility [patent_app_number] => 14/579487 [patent_app_country] => US [patent_app_date] => 2014-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 13396 [patent_no_of_claims] => 66 [patent_no_of_ind_claims] => 42 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14579487 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11082248 [patent_doc_number] => 20160279213 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-29 [patent_title] => 'Survivin-Directed Cancer Vaccine Therapy' [patent_app_type] => utility [patent_app_number] => 15/036629 [patent_app_country] => US [patent_app_date] => 2014-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 14445 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 19 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15036629 [rel_patent_id] =>[rel_patent_doc_number] =>)